Medical treatment of cardiovascular diseases in patients after hospitalization for COVID-19 (three-year follow-up data in the TARGET-VIP registry)

Aim. To evaluate the quality of drug treatment of patients with cardiovascular diseases (CVD) at the remote stage of follow-up after hospitalization for new coronavirus infection (COronaVIrus Disease 2019, COVID-19) within the framework of the prospective TARGET-VIP registry.

Material and methods. 1,130 people were included in the registry. The 473 (54.8%) patients with CVD were selected of the 863 patients discharged from the hospital with a diagnosis of COVID-19.

Results. The frequency of proper prescriptions of medicines upon discharge from the hospital was 60%, after 3 years this indicator decreased to 41.4% (p<0.001). During the 3-year follow-up, a clear trend was recorded in a decrease in the frequency of intake of all drugs, while for some groups of drugs this decrease reached statistically significant differences. The frequency of taking angiotensin converting enzyme inhibitors in patients with cerebral stroke, statins in coronary heart disease and statins in patients with cerebral stroke MI did not change significantly, although the frequency of taking these drugs at all stages of follow-up was very low and did not exceed a third of the required prescriptions. New CVD were detected in 51 patients, and the average frequency of taking proper medications for CVD was higher than in patients with already known stable CVD, 74.2% and 66.2%, respectively, p=0.047. The presence of CVD did not affect the quality of therapy in the new cases of CVD, the average frequency of taking the necessary drugs in these groups was 77.8 and 63.2%, respectively, p=0.074.

Conclusion. The quality of CVD therapy was insufficient at all stages of long-term follow-up: the frequency of proper prescriptions upon discharge from the hospital was 60%, after 3 years this indicator decreased to 41.4%. A clear trend was revealed in a decrease in the frequency of taking all drugs, while for some groups of drugs this decrease reached statistically significant differences. The quality of cardiovascular pharmacotherapy was higher with the appearance / development of new CVD in comparison with the group of stable patients with CVD, there was no significant improvement in the quality of therapy for previously observed CVD.

1. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected — obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17(3):135-49. DOI:10.1038/s41574-020-00462-1.

2. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430-6. DOI:10.1038/s41586-020-2521-4.

3. Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. J Community Health. 2020;45(6):1270-82. DOI:10.1007/s10900-020-00920-x.

4. Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. International register "Dynamics analysis of comorbidities in SARSCoV-2 survivors" (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Russian Journal of Cardiology. 2021;26(4):4470. (In Russ.) DOI:10.15829/1560-4071-2021-4470.

5. Liu H, Chen S, Liu M, et al. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. Aging Dis. 2020;11(3):668-678. DOI:10.14336/AD.2020.0502.

6. Zeymer U, Berkenboom G, Coufal Z, et al. APTOR investigators. Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR). Int J Cardiol. 2013;170(2):239-45. DOI:10.1016/j.ijcard.2013.10.057.

7. Frolova IA, Tarlovskaya EI, Romanov SV, et al. Impact of optimal therapy for noncommunicable diseases on the course and outcome of COVID-19 inpatients. Russian Journal of Cardiology. 2022;27(3):4845. (In Russ.) DOI:10.15829/1560-4071-2022-4845.

8. Wang T, Tan JB, Liu XL, et al. Barriers and enablers to implementing clinical practice guidelines in primary care: an overview of systematic reviews. BMJ Open. 2023;13(1):e062158. DOI:10.1136/bmjopen-2022-062158.

9. Yusuf S, Islam S, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231-43. DOI:10.1016/S0140-6736(11)61215-4.

10. Smirnov AA, Loukianov MM, Martsevich SYu, et al. Clinical and Anamnestic Characteristics, Cardiovascular Pharmacotherapy and Long-term Outcomes in Multimorbid Patients after COVID-19. Rational Pharmacotherapy in Cardiology. 2022;18(5):502-9. (In Russ.) DOI:10.20996/1819-6446-2022-09-06.

11. Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. Lipid profile changes after the acute COVID-19 period. Sub-analysis of the International Registry "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors" (AKTIV SARSCoV-2)" (12-month follow-up). Russian Journal of Cardiology. 2024;29(3):5716. (In Russ.) DOI: 10.15829/1560-4071-2024-5716.

12. Drapkina OM, Karpov OE, Lukyanov MM, et al. Prospective in-hospital registry of patients with suspected or documented COVID-19 infection and community-acquired pneumonia (TARGET-VIP): characteristics of patients and assessment of in-hospital outcomes. Cardiovascular Therapy and Prevention. 2020;19(6):2727. (In Russ.) DOI:10.15829/1728-8800-2020-2727.

13. Drapkina OM, Karpov OE, Lukyanov MM, et al. Experience of creating and the first results of the prospective hospital registry of patients with suspected or confirmed coronavirus infection (COVID-19) and community-acquired pneumonia (TARGET-VIP). Preventive medicine. 2020;23(8):6-13. (In Russ.) DOI:10.17116/profmed2020230816.

14. Martsevich SYu, Lukina YuV, Kutishenko NP, et al. Guidelines "Medical registries. Role in evidence-based medicine. Recommendations for creation": a brief review. Cardiovascular Therapy and Prevention. 2023;22(6):3615. (In Russ.) DOI:10.15829/1728-8800-2023-3615.

15. Konradi AO, Villevalde SV, Duplyakov DV, et al. An open-label multicenter observational study (registry) of patients recovered from coronavirus disease 2019 (COVID-19) with involvement of the cardiovascular system or with baseline severe cardiovascular diseases: rationale, design, and implications for clinical practice. Russian Journal of Cardiology. 2021;26(1):4287. (In Russ.) DOI:10.15829/1560-4071-2021-4287.

16. Alger HM, Rutan C, Williams JH 4th, et al. American Heart Association COVID-19 CVD Registry Powered by Get With The Guidelines. Circ Cardiovasc Qual Outcomes. 2020;13(8):e006967. DOI:10.1161/CIRCOUTCOMES.120.006967.

17. Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and out-comes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068-77. DOI:10.1016/j.cmet.20 20.04.021.

18. Kanorskii SG. Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic review. Kubanskii Nauchnyi Meditsinskii Vestnik. 2021;28(6):90–116. (In Russ.) DOI:10.25207/1608-6228-2021-28-6-90-116.

19. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-90. DOI:10.1038/s41591-022-01689-3.

20. Gilyarevsky SR, Golshmid MV, Bendeliani NG, et al. Efficacy of standard treatment for cardiovascular disease in COVID-19: hypotheses, evidence, and verification. Lechebnoe Delo. 2022;(1):12-19. (In Russ.) DOI:10.24412/2071-5315-2022-12491.

21. Kutishenko NP, Lukyanov MM, Martsevich SYu, et al. Medical treatment of patients with cardiovascular diseases during the first year after hospitalization for COVID-19. Cardiovascular Therapy and Prevention. 2022;21(12):3467. (In Russ.) DOI:10.15829/1728-8800-2022-3467.

22. Tyapaeva AR, Naumova EA, Semenova ON, et al. Medication adherence of cardiovascular patients after COVID-19: 6-month follow-up. Russian Journal of Cardiology. 2024;29(1S):5605. (In Russ.) DOI:10.15829/1560-4071-2024-5605.